Phase III clinical trial assessing AC201
Latest Information Update: 26 May 2025
At a glance
- Drugs AC-201-Accropeutics (Primary)
- Indications Psoriasis; Systemic lupus erythematosus
- Focus Therapeutic Use
Most Recent Events
- 20 May 2025 According to an Accropeutics media release, efficacy and safety findings from this Phase 2 trial support advancing AC-201 into Phase 3 development for plaque psoriasis.
- 05 Mar 2025 New trial record